Search results
Results from the WOW.Com Content Network
Immunotherapy helps the immune system to better act against cancer. What are the types of immunotherapy? Several types of immunotherapy are used to treat cancer.
Immunotherapy side effects happen when the immune system that has been prompted to act against the cancer also acts against healthy cells and tissues in the body. Learn about the types of side effects that immunotherapy might cause and where to go for more information.
Immunotherapy drugs called immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells. One such drug acts against a checkpoint protein called CTLA-4.
Immunotherapy uses the body’s immune system to fight cancer. This animation explains three types of immunotherapy used to treat cancer: nonspecific immune stimulation, T-cell transfer therapy, and immune checkpoint inhibitors.
Targeting proteins involved in T cell exhaustion may boost immunotherapy. Another obstacle with solid tumors is their surrounding environment. Physical barriers, for example, can prevent the infused CAR T cells from reaching tumor cells.
Researchers have launched a clinical trial to test an immunotherapy drug in patients who have both cancer and an autoimmune disease, such as rheumatoid arthritis, lupus, or multiple sclerosis. Immunotherapy drugs enhance the ability of the immune system to detect and kill tumor cells.
T-cell transfer therapy is a type of immunotherapy that makes your own immune cells better able to attack cancer. There are two main types of T-cell transfer therapy: tumor-infiltrating lymphocytes (or TIL) therapy and CAR T-cell therapy.
Learn more about immunotherapy to treat cancer. Stop cancer cells from growing by interrupting signals that cause them to grow and divide without order. Healthy cells in your body usually divide to make new cells only when they receive strong signals to do so.
The CCR’s Center for Immuno-oncology (CIO) explores fundamental questions of cancer immunotherapy through rigorous preclinical studies and translates these findings into clinical trials with the goal of developing novel therapies for a spectrum of cancers.
For some people with advanced esophageal cancer, two immunotherapy-based combination therapies are more effective than chemotherapy alone, which is the current standard treatment, according to the results of a large clinical trial.